Growth Factors and Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: closed (15 September 2023) | Viewed by 13960
Special Issue Editor
Interests: lung cancer; molecular biology; molecular targeted therapy; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Growth factor plays a pivotal role in lung cancer tumorigenesis by regulating multiple cellular processes such as cell proliferation, survival, invasion, and angiogenesis. Targeting a growth factor and its receptor has tremendous potential for the treatment of lung cancer. Growth factor is also crucial given that it involves intrinsic and acquired resistance to molecular targeted therapy and immunotherapy. One of the most extensively studied growth factors is vascular endothelial growth factor (VEGF), which promotes lung tumor growth and metastasis and confers resistance to various types of anti-cancer therapies by activating bypass pathways or modulating tumor immune microenvironments, and targeting VEGF has been shown to enhance the effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors or chemotherapy with/without immune checkpoint inhibitors in non-small-cell lung cancer. This Special Issue will highlight growth factors that affect lung tumorigenesis and therapeutic resistance, leading to a better understanding of the significance of growth factors as therapeutic targets and predictive/prognostic biomarkers in lung cancer. We welcome both original research and reviews that serve as a stepping stone toward further development of treatment strategy for lung cancer.
Dr. Noriaki Sunaga
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- non-small-cell lung cancer
- small cell lung cancer
- growth factor
- molecular targeted therapy
- immunotherapy
- tumor microenvironment
- drug resistance
- biomarker
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.